[go: up one dir, main page]

MX2024010047A - Metodos de tratamiento con celulas car en combinacion con moduladores del receptor s1p. - Google Patents

Metodos de tratamiento con celulas car en combinacion con moduladores del receptor s1p.

Info

Publication number
MX2024010047A
MX2024010047A MX2024010047A MX2024010047A MX2024010047A MX 2024010047 A MX2024010047 A MX 2024010047A MX 2024010047 A MX2024010047 A MX 2024010047A MX 2024010047 A MX2024010047 A MX 2024010047A MX 2024010047 A MX2024010047 A MX 2024010047A
Authority
MX
Mexico
Prior art keywords
treatment
combination
methods
receptor modulators
car cells
Prior art date
Application number
MX2024010047A
Other languages
English (en)
Inventor
Simone Dertschnig
Philippe Bousso
Morgane Boulch
Stephan Oehen
Original Assignee
Priothera Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Priothera Sas filed Critical Priothera Sas
Publication of MX2024010047A publication Critical patent/MX2024010047A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición de células CAR para usarse en el tratamiento de malignidades hematológicas en un sujeto en necesidad de la misma, en donde dicha célula CAR es una célula inmune que expresa una molécula de receptor de antígeno quimérico que se une a un antígeno relacionado con cáncer, y en donde una cantidad terapéuticamente efectiva de la composición de células CAR se administra en combinación con una cantidad terapéuticamente efectiva de un modulador del receptor S1P o una sal farmacéuticamente aceptable del mismo o un derivado de fosfato del mismo.
MX2024010047A 2022-02-16 2023-02-16 Metodos de tratamiento con celulas car en combinacion con moduladores del receptor s1p. MX2024010047A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305171 2022-02-16
EP22305781 2022-05-27
PCT/EP2023/053857 WO2023156506A1 (en) 2022-02-16 2023-02-16 Methods of treatment with car cells in combination with s1p receptor modulators

Publications (1)

Publication Number Publication Date
MX2024010047A true MX2024010047A (es) 2024-08-26

Family

ID=85227133

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010047A MX2024010047A (es) 2022-02-16 2023-02-16 Metodos de tratamiento con celulas car en combinacion con moduladores del receptor s1p.

Country Status (9)

Country Link
EP (1) EP4479083A1 (es)
JP (1) JP2025506506A (es)
KR (1) KR20240149401A (es)
AU (1) AU2023220748A1 (es)
CL (1) CL2024002407A1 (es)
IL (1) IL314940A (es)
MX (1) MX2024010047A (es)
TW (1) TW202341971A (es)
WO (1) WO2023156506A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4217620B2 (ja) 2001-09-27 2009-02-04 杏林製薬株式会社 ジアリールスルフィド誘導体とその付加塩及び免疫抑制剤
EP2172472B1 (en) 2003-02-18 2012-12-26 Kyorin Pharmaceutical Co., Ltd. Aminophosphonic acid derivative, salt thereof and modulator of S1P receptor
WO2006009092A1 (ja) 2004-07-16 2006-01-26 Kyorin Pharmaceutical Co., Ltd. 効果的な医薬の使用法及び副作用発現の防御に関する方法
CN101880250B (zh) 2004-10-12 2013-04-03 杏林制药株式会社 2-氨基-2-[2-[4-(3-苄氧基苯硫基)-2-氯苯基]乙基]-1,3-丙二醇盐酸盐或其水合物的制备方法及其制备中间体
ES2686424T5 (es) * 2010-05-04 2023-03-27 Yeda Res & Dev Inmunoterapia con células alogénicas redireccionadas
WO2012156958A2 (en) 2011-05-19 2012-11-22 Instituto De Medicina Molecular Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof
ES2873181T3 (es) 2013-02-20 2021-11-03 Priothera Ltd Tratamiento de la enfermedad de injerto contra huésped en pacientes trasplantados
JP2016539929A (ja) 2013-10-25 2016-12-22 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫療法のためのポリクローナルγδＴ細胞
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
US20170196910A1 (en) 2014-07-09 2017-07-13 Tc Biopharm Ltd Gamma delta t cells and uses thereof
EP3220926B1 (en) 2014-11-17 2024-12-25 Adicet Therapeutics, Inc. Engineered gamma delta t-cells
JP6799895B2 (ja) 2015-06-09 2020-12-16 リンファクト−リンフォサイト アクティベイション テクノロジーズ エス．エー． ＴＣＲγδ＋Ｔ細胞の生産方法
CN109069539A (zh) * 2016-02-18 2018-12-21 恩立夫克治疗有限责任公司 用于癌症治疗的联合免疫疗法和细胞因子控制疗法
MX2018013864A (es) 2016-05-12 2019-06-10 Adicet Bio Inc Métodos para la expansión selectiva de poblaciones de células t gama y composicicones de estas.
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies

Also Published As

Publication number Publication date
WO2023156506A1 (en) 2023-08-24
AU2023220748A1 (en) 2024-07-25
CL2024002407A1 (es) 2025-01-03
KR20240149401A (ko) 2024-10-14
IL314940A (en) 2024-10-01
TW202341971A (zh) 2023-11-01
JP2025506506A (ja) 2025-03-11
EP4479083A1 (en) 2024-12-25

Similar Documents

Publication Publication Date Title
PE20230821A1 (es) Anticuerpos anti-ccr8 para el tratamiento del cancer
CL2020002945A1 (es) Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t
CL2023002805A1 (es) Anticuerpos multiespecíficos egfr x cd28.
CL2020002036A1 (es) Terapia de combinación del cáncer que incluye proteínas de unión multiespecíficas que activan a las células asesinas naturales
CO2017011486A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales
BR112018075198A2 (pt) método para o tratamento de câncer ou uma doença associada a patógeno, composição farmacêutica, e kit
CO6140062A2 (es) Anticuerpos anti-trop-2 humanizados y quiméricos que median citotoxicidad de celulas cancerosas
BR112018067679A2 (pt) células que expressam múltiplas moléculas do receptor de antígeno quimérico (car) e seu uso
PE20220218A1 (es) Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso
BR112014019116A8 (pt) Kit, moléculas de anticorpo, composição farmacêutica, métodos de tratamento, usos, vetor, célula hospedeira e método de produção de uma molécula de anticorpo
PE20200757A1 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
MX2019013690A (es) Conjugados de farmaco-proteina con ciclodextrina.
AR092612A1 (es) Anticuerpos anti-cd3, moleculas de union a antigeno biespecificas que se unen a cd3 y cd20, y usos de los mismos
AR074203A1 (es) Terapia anti-angiogenesis para el tratamiento del cancer de mama. kit. uso.
CO2020006865A2 (es) Composiciones y métodos para el agotamiento de células cd5+
BR112022000231A2 (pt) Novos métodos
BR112018076639A2 (pt) quimioterapias de combinação
EA201690321A1 (ru) Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей
PE20231681A1 (es) Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usos
BR112022009290A2 (pt) Terapia para malignidades de células hematopoiéticas com o uso de células t geneticamente modificadas visando cd70
MX2021011750A (es) Anticuerpos anti-egfrviii y fragmentos de union a antigenos de los mismos.
AR121921A1 (es) Composiciones y métodos de tratamiento del cáncer con receptores de antígeno quimérico
CL2024002763A1 (es) Dosificación no lineal de mirdametinib
CL2024002016A1 (es) Anticuerpo modificado anti-pd-l1 humano; composición farmacéutica; y uso para tratar una enfermedad neurodegenerativa.
CL2024002407A1 (es) Métodos de tratamiento con células car en combinación con moduladores del receptor s1p.